Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Adimab LLC to discover and develop innovative antibody drugs in the oncology field.
Evotec SE and Novo Nordisk A/S have announced the launch of Lab En2, a translational drug discovery accelerator that aims to advance early research from academic institutions into novel therapeutics.
Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (Glycotargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.
Beactica Therapeutics AB has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS). The collaboration will focus on the translation of novel proteolysis-targeting degraders of TEAD under development by Beactica for treatment of cancer.
Novo Nordisk A/S and Valo Health Inc. have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases. The collaboration will leverage Valo’s Opal Computational Platform, including access to real-world patient data, artificial intelligence (AI)-enabled small-molecule discovery and Biowire human tissue modeling platform designed to speed up the discovery and development process.
Replay Holdings LLC has announced a research collaboration between Jura Bio Inc. and Syena, a cell therapy product company launched by Replay and the University of Texas MD Anderson Cancer Center earlier this year, to develop T-cell receptor (TCR)-based therapies.
Orionis Biosciences BV has established a multiyear collaboration with Genentech Inc., a member of the Roche Group, to discover novel small-molecule molecular glues for targets in major disease areas, including oncology and neurodegeneration.
Peptidream Inc. has entered into a new multitarget collaboration and license agreement with Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.
Benevolentai Ltd. has signed a strategic collaboration with Merck KGaA to identify novel drug candidates, initially for three targets in oncology, neurology and immunology.